|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.00 USD | -3.10% |
|
-4.29% | +8.70% |
| 06/05 | Wedbush Trims Price Target on Ultragenyx Pharmaceutical to $26 From $27, Maintains Neutral Rating | MT |
| 06/05 | Ultragenyx Pharmaceutical Q1 Loss Widens, Revenue Falls; Shares Down Pre-Bell | MT |
| Capitalization | 245.47Cr 211.23Cr 193.13Cr 184.27Cr 337.81Cr 24TCr 343.39Cr 2.32TCr 896.61Cr 11TCr 921.21Cr 901.48Cr 39TCr | P/E ratio 2026 * |
-5.52x | P/E ratio 2027 * | -33.4x |
|---|---|---|---|---|---|
| Enterprise value | 197.69Cr 170.12Cr 155.54Cr 148.4Cr 272.06Cr 19TCr 276.56Cr 1.87TCr 722.1Cr 9TCr 741.91Cr 726.01Cr 31TCr | EV / Sales 2026 * |
2.66x | EV / Sales 2027 * | 1.97x |
| Free-Float |
96.3% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ultragenyx Pharmaceutical Inc.
| 1 day | -3.10% | ||
| 1 week | -4.29% | ||
| Current month | +1.26% | ||
| 1 month | +1.96% | ||
| 3 months | +21.83% | ||
| 6 months | -24.43% | ||
| Current year | +8.70% |
| 1 week | 24.84 |  | 27.42 |
| 1 month | 23.68 | | 27.42 |
| Current year | 18.29 | | 27.42 |
| 1 year | 18.29 | | 42.37 |
| 3 years | 18.29 | | 60.37 |
| 5 years | 18.29 | | 115.25 |
| 10 years | 18.29 | | 179.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
CEO | Chief Executive Officer | 65 | 22/04/2010 |
Howard Horn
DFI | Director of Finance/CFO | 49 | 16/10/2023 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/05/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
BRD | Director/Board Member | 65 | 22/04/2010 |
Matthew Fust
BRD | Director/Board Member | 61 | 01/01/2014 |
Michael Narachi
BRD | Director/Board Member | 66 | 20/02/2015 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.10% | -4.29% | -29.80% | -46.46% | 245.47Cr | |
| -6.05% | -12.05% | -51.83% | -88.23% | 185.29Cr | |
| -3.40% | -0.20% | +7.34% | -6.84% | 34Cr | |
| -0.96% | -6.06% | -32.46% | - | 6.62Cr | |
| Average | -3.38% | -4.84% | -26.69% | -47.17% | 117.74Cr | |
| Weighted average by Cap. | -4.25% | -6.98% | -35.85% | -60.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 74Cr 64Cr 58Cr 56Cr 102.09Cr 7.12TCr 103.78Cr 700.25Cr 270.96Cr 3.38TCr 278.4Cr 272.43Cr 12TCr | 99Cr 85Cr 78Cr 74Cr 136.04Cr 9.48TCr 138.29Cr 933.13Cr 361.08Cr 4.5TCr 370.99Cr 363.04Cr 16TCr |
| Net income | -48Cr -41Cr -37Cr -36Cr -65Cr -4.57TCr -67Cr -449.18Cr -173.81Cr -2.17TCr -178.58Cr -174.75Cr -7.55TCr | -8.55Cr -7.36Cr -6.73Cr -6.42Cr -12Cr -820.5Cr -12Cr -81Cr -31Cr -389.5Cr -32Cr -31Cr -1.36TCr |
| Net Debt | -48Cr -41Cr -38Cr -36Cr -66Cr -4.58TCr -67Cr -450.99Cr -174.51Cr -2.18TCr -179.3Cr -175.46Cr -7.58TCr | -51Cr -44Cr -40Cr -38Cr -70Cr -4.88TCr -71Cr -479.93Cr -185.71Cr -2.32TCr -190.8Cr -186.72Cr -8.07TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/26/15 | 25.00 $ | -3.10% | 15,19,285 |
| 14/26/14 | 25.80 $ | -2.49% | 11,61,379 |
| 13/26/13 | 26.46 $ | -1.42% | 13,63,335 |
| 12/26/12 | 26.84 $ | +2.05% | 12,65,789 |
| 11/26/11 | 26.30 $ | +0.69% | 18,61,673 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- RARE Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition